News
About the PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
New Approaches to PCSK9 inhibition
Prof Derick Raal (University of Witwatersrand, Johannesburg, South Africa) discusses what’s in the pipeline for PCSK9 inhibition beyond the monoclonal antibodies
Read the report
Video: What's in the PCSK9 pipeline?
Watch the video
Hot Topics
Adverse effects of long-term statin therapy: New statement from the EAS Consensus Panel
Clinical trials have clearly proven the efficacy and short-term safety of statin treatment. But, with people taking these medications lifelong, are there any adverse effects to consider in the longer-term? This new statement weighs the evidence versus the perception of risk.
Video: EAS Consensus Panel: Statins do not impair cognitive function
Watch the video
Report: Neurocognitive effects and PCSK9 inhibition
Read the report
From the Editors
PCSK9 Monoclonal Antibody Therapy in Patients with Diabetes: Where We Are and Future NeedsProf Nathan D. Wong, Heart Disease Prevention Program, University of California, Irvine, USA
PCSK9 monoclonal antibody therapy has been shown to be effective in patients with diabetes. The next priority is to better define those primary prevention patients who would benefit most from treatment.
FOURIER: evolocumab in diabetes patients
Read the reportODYSSEY DM-DYSLIPIDEMIA with alirocumab
Read the reportLatest Views
Meet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie
Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
